글로벌 자가줄기세포 및 비줄기세포 기반 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 자가줄기세포 및 비줄기세포 기반 치료 시장

Data Bridge Market Research에 따르면 자가줄기세포 및 비줄기세포 기반 치료 시장은 2022~2029년 예측 기간 동안 4.25%의 CAGR로 성장할 것으로 예상되며, 2029년에는 1,322억 4,000만 달러에 도달할 것으로 예상됩니다.

자가 줄기세포 이식은 미분화된 세포 또는 줄기세포(다른 유형의 세포를 생성하는 세포)를 사람에게서 추출하여 수집한 다음 같은 사람에게 다시 이식하는 이식의 한 형태입니다. 조혈 줄기세포(혈액 세포의 전구체)가 조혈 줄기세포 이식에 더 일반적으로 사용되기 때문에 심장 세포는 때때로 심장 마비로 인한 손상을 복구하는 데 사용됩니다. 자가 줄기세포 이식과 이종 줄기세포 이식은 두 가지 유형의 줄기세포 이식입니다. 자가 줄기세포 이식은 자가유전자 또는 자가 줄기세포 이식 또는 자가-SCT라고도 합니다.

모든 연령대에서 암과 당뇨병의 유병률 증가는 자가 줄기세포 및 비줄기세포 기반 치료 시장의 성장률을 가속화하는 주요 원동력입니다. 시장 확대로 이어지는 또 다른 중요한 요인은 재생 의학 에서 새로운 자가 줄기세포 기반 치료의 출현입니다 . 나아가, 노령 인구의 증가와 자가 줄기세포 및 비줄기세포 기반 치료에 대한 수요의 급증은 시장 성장을 강화할 주요 원동력입니다. 의료 인식 증가 및 유리한 환불 정책과 같은 다른 중요한 요인은 시장 성장률을 완화할 것입니다.

게다가 개발 도상국의 광대한 미개척 시장과 연구 개발 활동의 증가는 자가줄기세포 및 비줄기세포 기반 치료 시장 성장에 유익한 기회를 제공할 것입니다.

However, high cost associated with autologous cellular therapies and the dearth of product innovations in the surgical sutures is the factors that will obstruct the market growth. The rising demand for advanced wound closure market and the lack of skilled professionals will challenge the autologous stem cell and non-stem cell based therapies market. Also, risks associated with the treatment such as diarrhea, vomiting, nausea, hair loss, infertility, severe infections and heart complications will act as market restraint and further impede the growth rate of market.

This autologous stem cell and non-stem cell based therapies market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on autologous stem cell and non-stem cell based therapies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Scope and Market Size

The autologous stem cell and non-stem cell based therapies market is segmented on the basis of type, product, application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on type, the autologous stem cell and non-stem cell based therapies market is segmented into autologous stem cells, and autologous non-stem cells.
• Based on product, the autologous stem cell and non-stem cell based therapies market is segmented into blood pressure (BP) monitoring devices, pulmonary pressure monitoring devices, and intracranial pressure (ICP) monitoring devices.
• Autologous stem cell and non-stem cell based therapies market is segmented based on the applications into neurodegenerative disorders, autoimmune diseases, cancer and tumors, and cardiovascular diseases.
• Based on end user, the autologous stem cell and non-stem cell based therapies market is segmented into hospitals and ambulatory surgical center.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Country Level Analysis

The autologous stem cell and non-stem cell based therapies market is analysed and market size insights and trends are provided by country, type, product, application and end user as referenced above.

The countries covered in the autologous stem cell and non-stem cell based therapies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the autologous stem cell and non-stem cell based therapies market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the minimizing risks involved with the therapy and well-developed healthcare infrastructure for the treatment of many infectious disorders in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the favourable reimbursement policies as well as tax and advanced healthcare infrastructure in this region.

The country section of the autologous stem cell and non-stem cell based therapies market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The autologous stem cell and non-stem cell based therapies market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for autologous stem cell and non-stem cell based therapies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the autologous stem cell and non-stem cell based therapies market. The data is available for historic period 2010 to 2020.

Competitive Landscape and Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Share Analysis

자가줄기세포 및 비줄기세포 기반 치료법 ​​시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 자가줄기세포 및 비줄기세포 기반 치료법 ​​시장과 관련된 회사의 초점에만 관련이 있습니다.

자가줄기세포 및 비줄기세포 기반 치료 시장의 주요 기업으로는 Caladrius Biosciences, Inc., Antria Inc., BrainStorm Cell Limited, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Opexa Therapeutics, Inc., Orgenesis Inc, Regeneus Ltd, US Stem Cell, Inc., Castle Creek Biosciences, Inc., Gilead Sciences, Inc., Novartis AG, Takeda Pharmaceutical Company Limited., NEOSTEM 등이 있습니다.

SKU-1757